Urolog. pro Praxi, 2008; 9(5): 223-229

Pharmacotherapy of benign prostatic hyperplasia

MUDr. Martina Poršová1, MUDr. Ivan Kolombo FEBU2, MUDr. Jaroslav Porš3, et al
1 Urologické oddělení, Klaudiánova nemocnice, Mladá Boleslav
2 Centrum robotické chirurgie a urologie Nemocnice Na Homolce, Praha
3 Urologická ambulance Městské nemocnice Turnov

Benign prostatatic hyperplasia (BPH) is the most frequent benign tumor in men. It is a chronic progressing disease, which is not life threatenning but its symptoms involve quality of life of the patients (23). The operation of prostate used to be the most common surgical procedure at older men in many countries in the past years. In last two decades, the treatment of BPH has changed. Nowdays, most fraquent treatment modality is farmakotherapy. Main effective drugs are alphablockers and inhibitors of 5-alpha reductase.

Keywords: benign prostatatic hyperplasia, farmakotherapy, alphablockers, inhibitors of 5-alpha reductase, fytotherapy

Published: December 20, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Poršová M, Kolombo I, Porš J, al E. Pharmacotherapy of benign prostatic hyperplasia. Urol. praxi. 2008;9(5):223-229.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abrams PH, Shah PJ, Stone AR, Choa RG. Bladder outflow obstruction treated with phenoxybenzamine. Br J Urol 1982; 54: 527-530. Go to original source... Go to PubMed...
    2. Andriole GL, Guess HA, Epstein JL, et al. Treatment with finasteride preserves usefulness of prostate specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficiency and Safety Study. Urology 1998; 52: 195-201. Go to original source... Go to PubMed...
    3. AUA. American Urological Association guidelines on management of benign prostatic hypeplasia, 2003. http://www.auanet.org.
    4. Ball AJ, Feneley RC, Abrams PH. The natural history of untreated prostatism. Br J Urol 1981; 53: 613-616. Go to original source... Go to PubMed...
    5. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5-alpha reductase inhibition in human benign prostatic hyperplasia. World J Urol 2002; 19: 413-425. Go to original source... Go to PubMed...
    6. Bruskewitz R, Girman CJ, Rowler J, et al. Effect of finasteride on bother and other healthrelated quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group (Proscar Long-term Efficasy and Safety Study). Urology 1999; 54(4): 670-678. Go to original source... Go to PubMed...
    7. de la Rosette J, Madersbacher S, Alivizatos G, et al. Guidelines EAU pro diagnostiku a léčbu benigní hyperplazie prostaty, EAU. Urol Listy 2004; 4: 71-103.
    8. Djavan B, Marberger M. A meta-analysis on the efficiency and tolerability oh alpha 1- adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia obstruction. Eur Urol 1988; 36: 1-13. Go to original source... Go to PubMed...
    9. Dvořáček J. Urologie praktického lékaře. Praha: ISV, 2000.
    10. European Association of Urology guidelines on benign prostatic hyperplasia (update March 2004).
    11. Hanno PM, Malkowicz SB, Wein AJ. Clinical manual of urology. Mc-Graw-Hill, New York 2001; 437-470.
    12. Hora M. Fytopreparáty v léčbě BPH. Urol Listy 2004; 4: 42-45.
    13. Isaacs JT. Importace of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Prostate 1990; 3(Suppl): 1-7. Go to original source... Go to PubMed...
    14. Kaplan SA, Slawin KM, Te AE. Benign prostatic hyperplasia: New diagnostic and treatment paradigma. AUA Annual Meeting, San Antonio 2005.
    15. Klečka J, Hora M, Běhounek P. Kombinovaná léčba benigní hyperplazie prostaty, ano či ne? Urolog. pro Praxi 2008; 9(2): 54-60.
    16. Kolombo I, et al. Benigní hyperplazie prostaty - BPH. Urolog. pro Praxi, 2008; 9(3): 138-142.
    17. Kolombo I. EUNI-Benigní hyperplázie prostaty. www.euni.cz.
    18. Mc Connell JD. The long term effects of medical therapy on progression of BPH: Results from the MTOPS trial. J Urol 2002; 167: 265, abstract 1042. Go to PubMed...
    19. Oesterling JE, Roy J, Agha A, Shown T, Kralup T, Johansen T, Lagerkvist M, Gormley G, Bach M, Waldstreicher J. Biologic variability of prostate specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group. Urology 1997; b50: 13-18. Go to original source... Go to PubMed...
    20. PDR Electronic Library. Physician Desk Reference 2004. Thomson Medical Economics. CD-ROM.
    21. Schwinn DA. The role of sloha-1-adrenergic receptor subtypes in lower urinary tract symptoms. Br J Urol 2001; 88: 27-34. Go to original source... Go to PubMed...
    22. Verner P. Benigní hyperplazie prostaty. Praha: Remedia, 2004; 24(4): 346-354.
    23. Verner P. Benigní hyperplazie prostaty. Současný přístup k farmakologické léčbě. Praha: Maxdorf, 2005.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.